Skip to main content
Premium Trial:

Request an Annual Quote

Strong TripleTOF 5600 Sales Drive Mid-Teens Q2 Growth at AB Sciex

Premium

AB Sciex saw mid-teens growth in the second quarter, driven by strong sales of the TripleTOF 5600 mass spectrometer, which "exceeded expectations," According to Larry Culp, president and CEO of AB Sciex parent firm Danaher.

In a conference call to discuss the firm's Q2 earnings, Culp also suggested that in the first half of the year AB Sciex "probably took a little bit of [market] share in certain corners" of the mass spec market, though he noted that the growth was also driven by strong demand for mass spec instruments generally, with pharma in particular performing "better in the first half of this year than anyone anticipated."

Demand for the company's mass spec instruments was "broad based," Culp said, "with research, applied, and pharma markets all growing in excess of 10 percent."

Culp also highlighted the release at June's American Society for Mass Spectrometry annual meeting of AB Sciex's new Selexion technology – a differential ion mobility technology for use on the 5600 and the QTRAP 5500.

Revenues for Danaher's Life Sciences and Diagnostics business grew 31 percent for the quarter, jumping to $704.8 million from $540.1 million a year ago.

Overall, Danaher's total sales increased 15 percent to $3.71 billion for the three months ended July 1, compared to $3.22 billion a year ago. Net earnings rose 74 percent to $648.8 million, or $.94 per share, from $372.5 million, or $.55 per share, a year ago.

R&D spending for the quarter jumped to $235.8 million, up 23 percent from $191.2 million for the second quarter of 2010, while SG&A expenses also rose 23 percent to $1.10 billion from $896.6 million a year ago.

As of July 1, Danaher reported $551.6 million in cash and cash equivalents.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.